Alogliptin – the new member of DPP-4 inhibitors class

Abstract

This review presents data on the efficacy and safety of alogliptin, a new representative of the DPP-4 inhibitors, in adult patients with type2 diabetes mellitus (DM type 2) as monotherapy or in combination with metformin, pioglitazone, glibenclamide and insulin.

Keywords

• alogliptin
• dpp-4 inhibitors
• efficacy
• safety
• cardiovascular risk
• hypoglycemia